APA (7th ed.) Citation

AP, S., S, V., L, H., CS, H., J, M., D, F., . . . AF, C. (2026). DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity. Cell reports. Medicine, 7(1), 102518. https://doi.org/10.1016/j.xcrm.2025.102518

Chicago Style (17th ed.) Citation

AP, Stockmann, et al. "DF6215, an α-optimized IL-2-Fc Fusion, Expands Immune Effectors and Drives Robust Preclinical Anti-tumor Activity." Cell Reports. Medicine 7, no. 1 (2026): 102518. https://doi.org/10.1016/j.xcrm.2025.102518.

MLA (9th ed.) Citation

AP, Stockmann, et al. "DF6215, an α-optimized IL-2-Fc Fusion, Expands Immune Effectors and Drives Robust Preclinical Anti-tumor Activity." Cell Reports. Medicine, vol. 7, no. 1, 2026, p. 102518, https://doi.org/10.1016/j.xcrm.2025.102518.